Ceritinib-d7

Ceritinib-d7 is a deuterium labeled Ceritinib. Ceritinib is a selective, orally bioavailable and ATP-competitive ALK tyrosine kinase inhibitor[1].

Product Specifications

CAS Number

[1632484-77-5]

Product Name Alternative

LDK378 D7

UNSPSC

12352005

Target

Anaplastic lymphoma kinase (ALK) ; IGF-1R; Insulin Receptor; Isotope-Labeled Compounds

Type

Isotope-Labeled Compounds

Related Pathways

Others; Protein Tyrosine Kinase/RTK

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Cancer; Endocrinology

Purity

98.00

Solubility

10 mM in DMSO|DMSO : ≥ 12.5mg/mL

Smiles

CC1=C(C2CCNCC2)C=C(OC(C([2H])([2H])[2H])([2H])C([2H])([2H])[2H])C(NC3=NC=C(Cl)C(NC4=CC=CC=C4S(=O)(C(C)C)=O)=N3)=C1

Molecular Formula

C28H29D7ClN5O3S

Molecular Weight

565.18

References & Citations

[1]Marsilje TH, et al. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2- (2-isopropoxy-5-methyl-4- (piperidin-4-yl) phenyl) -N4- (2- (isopropylsulfonyl) phenyl) pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem. 2013 Jul 25;56 (14) :5675-90.